This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Multiple sclerosis is a complex neurological condition that requires evaluation by a qualified healthcare professional. Always consult a board-certified neurologist or other licensed healthcare provider with any questions regarding your health, symptoms, or test results. Never disregard professional medical advice or delay seeking it based on content you read here. If you are experiencing a medical emergency, call 911 or your local emergency services immediately.
🔍 What Is Multiple Sclerosis Diagnosis? — Quick Answer
Multiple sclerosis (MS) is diagnosed through a combination of clinical evaluation, neurological examination, and diagnostic testing — there is no single definitive test. The process relies on the McDonald Criteria (2017 revision), which require evidence of demyelination disseminated in space (DIS) and disseminated in time (DIT), while excluding alternative diagnoses.
Key diagnostic tools:
- MRI with gadolinium — brain and spinal cord (90–95% sensitivity)
- Lumbar puncture — CSF analysis for oligoclonal bands (OCBs) and IgG index
- Evoked potentials — visual, brainstem auditory, and somatosensory
- Blood tests — to rule out mimics (lupus, Lyme, vitamin B12 deficiency, etc.)
Bottom line: Early diagnosis and treatment significantly improve long-term outcomes. If you suspect MS symptoms, seek evaluation by a neurologist promptly.
📖 Table of Contents
- Understanding MS Diagnosis
- Early Signs and Symptoms
- The Neurological Examination
- MRI: Brain and Spine Imaging
- Lumbar Puncture (CSF Analysis)
- Evoked Potentials
- McDonald Criteria (2017 Revision)
- MS Types and Disease Course
- Differential Diagnosis
- 10 Questions to Ask Your Neurologist
- Frequently Asked Questions
- References
1. Understanding MS Diagnosis
Multiple sclerosis (MS) is a chronic, immune-mediated demyelinating disease of the central nervous system (CNS) that affects approximately 2.8 million people worldwide (GBD 2016 Neurology Collaborators, 2019). In the United States, the prevalence has risen to nearly 1 million adults (Wallin et al., 2019).
The diagnosis of MS has evolved dramatically over the past two decades. Before the widespread adoption of MRI and standardized criteria, many patients lived for years — sometimes decades — without a definitive diagnosis. Today, the McDonald Criteria (named after neurologist W. Ian McDonald) provide a structured framework that enables earlier and more accurate diagnosis while minimizing false positives.
Despite these advances, diagnosing MS remains challenging. There is no single pathognomonic test. Instead, clinicians must integrate findings from the patient history, neurological examination, MRI, cerebrospinal fluid (CSF) analysis, and evoked potential studies to build a cohesive diagnostic picture (Thompson et al., 2018). The core principle is to demonstrate that CNS damage has occurred in multiple locations (dissemination in space) and at different time points (dissemination in time), while excluding conditions that can mimic MS.
2. Early Signs and Symptoms of MS
MS can present with a remarkable variety of neurological symptoms depending on the location of demyelinating lesions within the CNS. No two patients have identical presentations, which contributes to the diagnostic difficulty. The most common presenting symptoms include:
👁️ Optic Neuritis
Sudden or subacute monocular vision loss, often with pain on eye movement (retrobulbar pain). Affects ~20% of patients at presentation. Most patients recover vision over weeks, but residual deficits are common.
🦵 Motor Weakness
Focal weakness, often affecting one limb (monoparesis) or one side of the body (hemiparesis). Typically reflects corticospinal tract involvement. Spasticity and hyperreflexia are associated findings.
🫨 Sensory Disturbances
Numbness, tingling, “pins and needles” (paresthesias), or a band-like sensation around the trunk (the “MS hug”). Trigeminal neuralgia is also more common in MS than in the general population.
⚡ Brainstem Symptoms
Diplopia (double vision) from internuclear ophthalmoplegia (INO), vertigo, dysarthria, dysphagia, or facial numbness. Lhermitte sign — an electric-shock sensation down the spine with neck flexion — is highly suggestive.
🚶 Gait and Balance Issues
Cerebellar involvement causes ataxia, intention tremor, and wide-based gait. Combined with weakness and spasticity, gait impairment is a major contributor to disability progression.
🧠 Fatigue and Cognition
MS-related fatigue affects 80% of patients. Cognitive symptoms include slowed processing speed, impaired memory, and difficulty with executive function. Mood disorders, especially depression, are common.
• Sudden vision loss in one eye
• Acute double vision lasting more than a few hours
• New-onset focal weakness or numbness spreading over hours to days
• Electric-shock sensations with neck movement
• Gait instability or unexplained falls
Clinically Isolated Syndrome (CIS)
Many patients experience a first demyelinating episode — a monophasic neurological event that lasts at least 24 hours and is consistent with inflammatory demyelination. This is called a clinically isolated syndrome (CIS). Not all patients with CIS go on to develop MS, but the presence of MRI lesions significantly increases the risk of conversion. In landmark studies, patients with CIS and abnormal MRI had a 60–80% risk of developing clinically definite MS within 20 years, compared to ~20% in those with normal MRI (Fisniku et al., 2008).
3. The Neurological Examination
A thorough neurological examination is the foundation of the MS diagnostic process. The neurologist will systematically assess:
- Cranial nerves: Visual acuity, color vision (red desaturation), pupillary response (relative afferent pupillary defect in optic neuritis), extraocular movements (nystagmus, INO), facial sensation and strength, hearing, and gag reflex.
- Motor system: Muscle strength (Medical Research Council scale), tone (spasticity), and bulk. Asymmetry is a key finding.
- Sensory system: Light touch, pinprick, temperature, vibration (tuning fork), and proprioception mapped to dermatomes.
- Cerebellar function: Finger-to-nose test, heel-to-shin test, rapid alternating movements (dysdiadochokinesia), and Romberg test.
- Gait: Heel walking, toe walking, tandem gait (straight line), and timed 25-foot walk.
- Reflexes: Deep tendon reflexes (hyperreflexia suggests upper motor neuron involvement), Babinski sign (extensor plantar response), and Hoffmann sign.
🏥 Clinical Pearl: The Kurtzke Expanded Disability Status Scale (EDSS) is the most widely used tool for quantifying neurological impairment in MS. It ranges from 0 (normal neurological exam) to 10 (death due to MS). While primarily used in research and clinical trials, many neurologists use a functional system score in routine practice to track changes over time (Kurtzke, 1983).
4. MRI: Brain and Spine Imaging
Magnetic resonance imaging (MRI) is the most sensitive paraclinical tool for diagnosing MS. It is used to visualize demyelinating plaques (lesions) in the brain, optic nerves, and spinal cord, and to assess for dissemination in space and time.
MRI Protocol for Suspected MS
The standardized MRI protocol recommended by the Consortium of MS Centers (CMSC) and MAGNIMS includes (Wattjes et al., 2021):
| Sequence | Purpose |
|---|---|
| T2-weighted / FLAIR | Detects hyperintense lesions (plaques) in brain parenchyma. FLAIR suppresses CSF signal, making periventricular lesions more conspicuous. |
| T1-weighted pre-contrast | Shows “black holes” — chronic lesions with severe tissue destruction (hypointense on T1). |
| T1-weighted post-gadolinium | Enhancing lesions indicate active inflammation and breakdown of the blood-brain barrier within the past ~4–6 weeks. This is the gold standard for demonstrating DIT on a single scan. |
| STIR / T2-weighted (spinal cord) | Short Tau Inversion Recovery (STIR) is the optimal sequence for detecting spinal cord lesions, which are highly specific for MS. |
| 3D T1 MPRAGE | High-resolution volumetric acquisition for assessing brain atrophy, increasingly recognized as a biomarker of disease progression. |
Characteristic MRI Findings in MS
MS lesions have several characteristic features that help distinguish them from other white matter diseases:
- Periventricular location: Lesions adjacent to the lateral ventricles (“Dawson fingers” — ovoid lesions oriented perpendicular to the ventricles, reflecting perivenular inflammation).
- Juxtacortical location: Lesions involving U-fibers just beneath the cortical gray matter.
- Infratentorial location: Lesions in the brainstem, cerebellum, or spinal cord — particularly specific for MS.
- Spinal cord lesions: Typically involve fewer than 2 vertebral segments, occupy the peripheral white matter, and rarely cause cord expansion (unlike neuromyelitis optica spectrum disorder).
- Optic nerve enhancement: Visible on dedicated coronal fat-suppressed sequences with gadolinium.
Gadolinium-Enhancing Lesions and DIT
The presence of both gadolinium-enhancing (active) and non-enhancing (chronic) lesions on a single MRI scan constitutes evidence of dissemination in time (DIT) under the 2017 McDonald criteria. This is a critical advantage — a single scan may be sufficient to meet the DIT requirement when enhancement is present (Thompson et al., 2018).
• Sensitivity for MS diagnosis: 90–95%
• Specificity: ~85% (varies by population and comparator group)
• Spinal cord MRI alone has ~80% sensitivity but very high specificity (>90%)
Important caveat: White matter hyperintensities are non-specific and can be seen in migraine, hypertension, small-vessel disease, and aging. Experienced neuroradiologists use standardized reporting systems (e.g., BRAVO, MAGNIMS) to improve diagnostic accuracy.
5. Lumbar Puncture (CSF Analysis)
Cerebrospinal fluid (CSF) analysis obtained via lumbar puncture (spinal tap) provides critical evidence of intrathecal inflammation. While not required for diagnosis in all cases, it is especially valuable when clinical presentation is atypical, MRI findings are inconclusive, or alternative diagnoses are being considered.
Key CSF Findings in MS
| Test | Typical MS Finding | Interpretation |
|---|---|---|
| Oligoclonal bands (OCBs) | ≥2 unique bands in CSF that are absent in serum | Evidence of intrathecal IgG synthesis; the most sensitive CSF marker for MS. Present in >85% of patients with confirmed MS (Gasperi et al., 2022). |
| IgG index | >0.7 (or >0.85 in some labs) | Quantifies intrathecal IgG production. Formula: (CSF IgG / CSF albumin) ÷ (serum IgG / serum albumin). |
| White blood cell count | 5–50 cells/μL (lymphocytic predominance) | Mild pleocytosis. >>50 cells suggests alternative diagnosis (e.g., infection, neurosarcoidosis, CNS lymphoma). |
| Total protein | Normal or mildly elevated (45–70 mg/dL) | Markedly elevated protein is not typical for MS and should prompt investigation for other causes. |
What to Expect During a Lumbar Puncture
The procedure is performed by a trained clinician with the patient lying on their side (lateral decubitus) or sitting and leaning forward. After local anesthesia, a thin needle is inserted between the L3–L4 or L4–L5 vertebrae to collect CSF. Most patients experience only mild pressure or discomfort. A post-dural puncture headache occurs in approximately 10–30% of cases, usually self-limiting with hydration and rest. Serious complications are rare (Ehrlich et al., 2016).
The presence of CSF OCBs is such a strong predictor of MS conversion after a first clinical episode that the 2017 McDonald criteria added it as an alternative to DIT. A patient with CIS who has both MRI evidence of DIS and CSF-specific OCBs meets the criteria for MS diagnosis — even without a second clinical attack or new MRI lesion (Thompson et al., 2018).
6. Evoked Potentials
Evoked potentials (EPs) measure the electrical conduction velocity along specific neural pathways. They can reveal demyelination that is clinically silent — that is, damage to a nerve pathway that has not yet produced noticeable symptoms. This makes them valuable for demonstrating dissemination in space.
Types of Evoked Potentials Used in MS
- Visual evoked potentials (VEPs): Most useful in MS. A delayed P100 waveform latency in one or both eyes indicates demyelination of the optic nerve, even without a history of optic neuritis. Abnormal in 80–90% of MS patients.
- Brainstem auditory evoked potentials (BAEPs): Assess the auditory pathway through the brainstem. Abnormal interpeak latencies suggest brainstem demyelination. Less sensitive than VEPs (~50%).
- Somatosensory evoked potentials (SSEPs): Stimulate peripheral nerves (median at wrist, tibial at ankle) and measure conduction through the dorsal columns of the spinal cord. Useful for detecting spinal cord lesions.
While MRI has largely supplanted evoked potentials for routine diagnostic use, they remain helpful in specific scenarios — particularly when MRI is contraindicated or equivocal, or when the clinical picture requires additional objective evidence of demyelination (Hardmeier et al., 2017).
7. McDonald Criteria (2017 Revision)
The McDonald Criteria provide the internationally accepted diagnostic framework for MS. They were first published in 2001, revised in 2005, 2010, and most recently in 2017. The 2017 revision (published in The Lancet Neurology) is the current standard (Thompson et al., 2018).
Core Diagnostic Principles
The criteria rest on two fundamental concepts:
- Dissemination in Space (DIS): Clinical or MRI evidence of at least two distinct CNS lesions (in typical MS locations — periventricular, cortical/juxtacortical, infratentorial, or spinal cord). Under the 2017 revision, DIS requires ≥1 T2-hyperintense lesion in at least 2 of 4 CNS areas.
- Dissemination in Time (DIT): Evidence that lesions have occurred at different time points. This can be demonstrated by: (a) a new T2 or gadolinium-enhancing lesion on follow-up MRI, or (b) the simultaneous presence of gadolinium-enhancing and non-enhancing lesions on a single scan, or (c) the presence of CSF-specific oligoclonal bands.
Diagnostic Algorithm (2017 McDonald Criteria)
| Clinical Presentation | Additional Data Needed for MS Diagnosis |
|---|---|
| ≥2 clinical attacks; objective clinical evidence of ≥2 lesions | None — clinical evidence alone is sufficient (if no alternative diagnosis explains the presentation) |
| ≥2 clinical attacks; objective clinical evidence of 1 lesion | DIS demonstrated by: ≥1 T2 lesion in at least 2 MS-typical CNS areas on MRI, OR a second clinical attack involving a different CNS site |
| 1 clinical attack; objective clinical evidence of ≥2 lesions | DIT demonstrated by: simultaneous gadolinium-enhancing + non-enhancing lesions on MRI, OR new T2/enhancing lesion on follow-up MRI, OR CSF-specific OCBs |
| 1 clinical attack; objective clinical evidence of 1 lesion (CIS) | DIS + DIT (both required). DIS: ≥1 T2 lesion in 2 of 4 MS-typical areas. DIT: any of the three methods above. |
| Progressive neurological progression suggestive of PPMS | 1 year of disease progression (retrospective or prospective) plus ≥2 of: (1) ≥1 T2 lesion in ≥1 MS-typical brain area; (2) ≥2 T2 spinal cord lesions; (3) CSF OCBs |
Key Changes in the 2017 Revision
- CSF OCBs can substitute for DIT: This was the most impactful change. Previously, DIT required MRI evidence of new lesion formation over time. Now, the presence of CSF-specific OCBs in a patient with a single clinical attack and MRI evidence of DIS is sufficient for diagnosis.
- Cortical lesions recognized: The 2017 criteria explicitly include cortical (intracortical/leukocortical) lesions as MS-typical locations alongside juxtacortical lesions.
- Simplification of DIS: The requirement remains ≥1 T2 lesion in at least 2 of 4 MS-characteristic CNS areas (periventricular, cortical/juxtacortical, infratentorial, spinal cord).
- Symptomatic lesions can be counted: In patients with brainstem or spinal cord syndromes, symptomatic lesions in those regions can be used to demonstrate DIS — a change from the 2010 criteria where they were excluded.
8. MS Types and Disease Course
Once MS is diagnosed, the neurologist will classify the disease course. The four main phenotypes, defined by the 2013 Lublin-Revised Classification (Lublin et al., 2014), guide treatment decisions and prognosis:
🏁 Clinically Isolated Syndrome (CIS)
A first episode of neurological symptoms lasting ≥24 hours, caused by inflammatory demyelination. Not all CIS converts to MS, but high-risk features (multiple MRI lesions, CSF OCBs) strongly predict conversion.
🔄 Relapsing-Remitting MS (RRMS)
The most common form (~85% at onset). Characterized by clearly defined acute relapses (attacks) followed by partial or complete recovery periods. Between relapses, there is no disease progression.
📈 Secondary Progressive MS (SPMS)
An initial RRMS course that transitions to progressive worsening of neurological function, with or without occasional relapses. About 50% of RRMS patients transition to SPMS within 15–20 years without treatment.
📉 Primary Progressive MS (PPMS)
Progressive disability from onset, without relapses. Accounts for ~10–15% of MS cases. MRI often shows less inflammatory activity (fewer gadolinium-enhancing lesions) compared to RRMS. Diagnosis requires 1 year of progression plus ≥2 supportive criteria.
🧬 Emerging Concept — MS Subtypes: Research increasingly suggests that MS exists on a spectrum rather than in distinct categories. Biomarkers such as neurofilament light chain (NfL), serum GFAP, and advanced MRI metrics (central vein sign, paramagnetic rim lesions) are being studied to refine disease classification and predict treatment response (Kuhle et al., 2023).
9. Differential Diagnosis
Many conditions can mimic MS, which is why excluding alternative diagnoses is a critical component of the diagnostic process. The “MS mimics” include:
| Category | Condition | Key Distinguishing Features |
|---|---|---|
| Autoimmune | Neuromyelitis optica spectrum disorder (NMOSD) | Longitudinally extensive transverse myelitis (≥3 vertebral segments), aquaporin-4 IgG seropositivity, optic neuritis that is severe and often bilateral. Anti-MOG antibody disease is a related entity. |
| Autoimmune | Systemic lupus erythematosus (SLE) | Multisystem involvement (skin, joints, kidneys), serology (ANA, anti-dsDNA), and central nervous system involvement that is typically more vascular than demyelinating. |
| Autoimmune | Sarcoidosis (neurosarcoidosis) | Leptomeningeal enhancement, pulmonary involvement, elevated ACE, non-caseating granulomas on biopsy. |
| Infectious | Lyme disease (neuroborreliosis) | History of tick exposure, erythema migrans rash, positive Borrelia serology (CSF:serum antibody index). |
| Infectious | HIV-associated CNS disease | HIV seropositivity, diffuse white matter involvement, different clinical course. |
| Vascular | Cerebral small-vessel disease | Hypertension, diabetes, age-related periventricular/confluent white matter changes, lacunar infarcts, lack of gadolinium enhancement. |
| Vascular | Susac syndrome | Triad of encephalopathy, hearing loss, and retinopathy. MRI shows “snowball” lesions in corpus callosum, typically sparing the periventricular region. |
| Metabolic | Vitamin B12 deficiency | Subacute combined degeneration of the spinal cord, macrocytic anemia, low B12 levels, elevated homocysteine/methylmalonic acid. |
| Genetic | Leukodystrophies (adult-onset) | Family history, symmetric confluent white matter involvement, specific metabolic/genetic testing (e.g., adrenoleukodystrophy). |
10. 10 Questions to Ask Your Neurologist
Being diagnosed with MS or undergoing evaluation for it can be overwhelming. These questions will help you have a productive conversation with your neurologist:
- What type of MS do I have, and what does that mean for my prognosis?
- Based on my MRI and other tests, how active is my disease? (Ask about lesion count, location, gadolinium enhancement, and brain atrophy.)
- Do I meet the McDonald criteria for a definitive diagnosis, or am I still in the evaluation phase?
- What treatment options are available, and how do we decide which disease-modifying therapy (DMT) is right for me? (Discuss efficacy, side effects, monitoring requirements, and route of administration.)
- How often should I have follow-up MRIs, and what are we looking for on each scan?
- What symptoms should prompt me to call your office or go to the emergency room?
- Are there lifestyle changes — diet, exercise, vitamin D, smoking cessation — that can improve my outcomes?
- What specialists should I have on my care team? (Consider MS nurse specialist, physical/occupational therapist, ophthalmologist, urologist, psychologist.)
- Should I consider a second opinion at an MS center of excellence or participate in a clinical trial?
- What resources are available for support, education, and financial assistance? (National MS Society, MSAA, local support groups, drug copay assistance programs.)
11. Frequently Asked Questions
How long does it take to diagnose MS?
The diagnostic timeline varies widely. Some patients receive a diagnosis within weeks of their first symptom if MRI shows characteristic lesions and gadolinium enhancement (demonstrating DIS + DIT on a single scan). Others may undergo months to years of monitoring, particularly if the initial presentation is atypical, MRI findings are equivocal, or symptoms are mild. The average time from symptom onset to diagnosis has improved significantly with modern criteria and may be as short as 3–6 months for typical presentations.
Can MS be diagnosed without an MRI?
Yes, but it is uncommon. The McDonald criteria allow for a purely clinical diagnosis if a patient has experienced ≥2 clinical attacks with objective evidence of ≥2 separate CNS lesions and alternative diagnoses have been excluded. However, in practice, MRI is almost always performed because it provides critical information about lesion burden, activity, and location that clinical examination alone cannot. MRI also helps exclude mimics and establishes a baseline for monitoring disease progression.
Is a lumbar puncture always necessary for MS diagnosis?
No. A lumbar puncture is not required when clinical and MRI findings clearly meet the McDonald criteria for DIS and DIT. However, it is strongly recommended when: (1) the presentation is atypical; (2) MRI findings are inconclusive or insufficient; (3) the patient has had only one clinical attack (CIS) and MRI shows DIS but not DIT; or (4) alternative diagnoses need to be excluded. CSF analysis demonstrating oligoclonal bands can substitute for MRI evidence of DIT under the 2017 criteria.
What is a “clinically isolated syndrome” (CIS)?
A clinically isolated syndrome (CIS) is a first episode of neurological symptoms lasting at least 24 hours, caused by inflammatory demyelination in the CNS. Examples include optic neuritis, partial myelitis, or a brainstem syndrome. CIS is not MS — it is a single, monophasic event. However, if MRI shows silent lesions consistent with demyelination, the risk of converting to clinically definite MS is substantially elevated. About 60–80% of patients with CIS and abnormal MRI develop MS within 20 years (Fisniku et al., 2008).
What are oligoclonal bands and why do they matter?
Oligoclonal bands (OCBs) are proteins (immunoglobulin G) that appear as distinct bands when CSF is analyzed by electrophoresis. In MS, OCBs are found in the CSF but not in the patient’s serum, indicating that the immune system is producing antibodies within the CNS (intrathecal synthesis). The presence of ≥2 unique CSF bands is found in >85% of MS patients and is considered strong evidence of an inflammatory CNS process. Under the 2017 McDonald criteria, CSF-specific OCBs can substitute for MRI-based evidence of dissemination in time, enabling an MS diagnosis after a single clinical attack if DIS is also confirmed on MRI.
Can stress or diet cause MS?
No. The exact cause of MS is not fully understood, but it is believed to result from a combination of genetic susceptibility (the strongest association is with the HLA-DRB1*15:01 allele) and environmental triggers (EBV infection, low vitamin D levels, smoking, and adolescent obesity). Stress and diet do not cause MS, but stress is associated with an increased risk of relapses, and certain dietary patterns may influence overall well-being and comorbid conditions. The strongest modifiable risk factors are vitamin D sufficiency and avoidance of smoking (Waubant et al., 2019).
What is the difference between RRMS and PPMS?
Relapsing-remitting MS (RRMS) is characterized by acute attacks (relapses) with partial or complete recovery and no disease progression between attacks. It accounts for ~85% of initial MS diagnoses. Primary progressive MS (PPMS) involves steady neurological worsening from disease onset without relapses. PPMS patients tend to be older at onset (average age ~40 vs. ~30 for RRMS), have equal male-to-female ratios (vs. 3:1 female predominance in RRMS), and typically show less inflammatory activity on MRI (fewer gadolinium-enhancing lesions). Treatment approaches differ: many DMTs approved for RRMS are not effective in PPMS. Ocrelizumab (Ocrevus) is the first and only therapy approved for PPMS as of 2025 (Montalban et al., 2017).
Can I have MS with a normal MRI?
Yes, it is possible but uncommon. Approximately 5–10% of patients with confirmed MS may have a normal brain MRI at the time of diagnosis, particularly in the early stages. However, many of these patients will have abnormalities on spinal cord MRI or on dedicated sequences. A completely normal high-quality 3T MRI (brain and spinal cord) makes MS very unlikely and should prompt reconsideration of the diagnosis and investigation for mimics. If clinical suspicion remains high, repeat MRI in 6–12 months may reveal new lesions.
How accurate are blood tests for diagnosing MS?
There is no blood test that can diagnose MS. However, blood tests are essential in the diagnostic workup to rule out conditions that mimic MS (e.g., lupus, B12 deficiency, Lyme disease, HIV, neurosarcoidosis). Blood tests for MS biomarkers, such as serum neurofilament light chain (NfL), are being increasingly used in research and some clinical settings to monitor disease activity and treatment response, but they are not yet part of formal diagnostic criteria (Kuhle et al., 2023).
What should I do if I think I have MS symptoms?
If you are experiencing neurological symptoms that concern you — especially vision changes, focal weakness, sensory disturbances, or gait problems — schedule an appointment with a primary care physician or a neurologist. Keep a symptom diary documenting the date, nature, duration, and severity of each symptom. Bring a list of all medications, family history, and any prior imaging or lab results. While waiting for your appointment, there is no need to restrict activities unless symptoms affect safety (e.g., driving with vision changes). Do not start any treatments or supplements without medical guidance.
References
- Thompson, A. J., Banwell, B. L., Barkhof, F., et al. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, 17(2), 162–173. https://doi.org/10.1016/S1474-4422(17)30470-2
- Wallin, M. T., Culpepper, W. J., Campbell, J. D., et al. (2019). The prevalence of MS in the United States. Neurology, 92(10), e1029–e1040. https://doi.org/10.1212/WNL.0000000000007035
- GBD 2016 Neurology Collaborators. (2019). Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 18(5), 459–480. https://doi.org/10.1016/S1474-4422(19)30417-3
- Comi, G., Bar-Or, A., Lassmann, H., et al. (2021). Role of early treatment in the management of multiple sclerosis. Journal of Neurology, 268, 3196–3212. https://doi.org/10.1007/s00415-021-10550-9
- Fisniku, L. K., Brex, P. A., Altmann, D. R., et al. (2008). Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain, 131(3), 808–817. https://doi.org/10.1093/brain/awm329
- Lublin, F. D., Reingold, S. C., Cohen, J. A., et al. (2014). Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology, 83(3), 278–286. https://doi.org/10.1212/WNL.0000000000000560
- Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 33(11), 1444–1452. https://doi.org/10.1212/WNL.33.11.1444
- Wattjes, M. P., Ciccarelli, O., Reich, D. S., et al. (2021). 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. The Lancet Neurology, 20(8), 653–670. https://doi.org/10.1016/S1474-4422(21)00095-8
- Gasperi, C., Salmen, A., Antony, G., et al. (2022). Association of intrathecal immunoglobulin G synthesis with disability worsening in multiple sclerosis. Journal of Neurology, 269, 3554–3563. https://doi.org/10.1007/s00415-022-10953-2
- Hardmeier, M., Leocani, L., & Fuhr, P. (2017). A new role for evoked potentials in MS? Reproducibility of the multichannel ASSR. Clinical Neurophysiology, 128(1), e1–e2. https://doi.org/10.1016/j.clinph.2016.10.092
- Montalban, X., Hauser, S. L., Kappos, L., et al. (2017). Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine, 376, 209–220. https://doi.org/10.1056/NEJMoa1606468
- Kuhle, J., Kropshofer, H., Haering, D. A., et al. (2023). Blood neurofilament light chain as a biomarker of disease activity and treatment response in multiple sclerosis. Nature Reviews Neurology, 19, 261–275. https://doi.org/10.1038/s41582-023-00808-3
- Waubant, E., Lucas, R., Mowry, E., et al. (2019). Environmental and genetic risk factors for MS: an integrated review. Annals of Clinical and Translational Neurology, 6(9), 1905–1922. https://doi.org/10.1002/acn3.50882
- Ehrlich, D. E., Li, D. K. B., & Traboulsee, A. L. (2016). The utility of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. Neurology: Clinical Practice, 6(4), 305–313. https://doi.org/10.1212/CPJ.0000000000000205
- Polman, C. H., Reingold, S. C., Banwell, B., et al. (2011). Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology, 69(2), 292–302. https://doi.org/10.1002/ana.22366
- McDonald, W. I., Compston, A., Edan, G., et al. (2001). Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology, 50(1), 121–127. https://doi.org/10.1002/ana.1032
- Filippi, M., Preziosa, P., & Rocca, M. A. (2022). MRI-based biomarkers for multiple sclerosis: an update. The Lancet Neurology, 21(9), 803–819. https://doi.org/10.1016/S1474-4422(22)00219-8
📌 Disclaimer: This article is for educational purposes only and does not constitute medical advice. Medical information changes rapidly. While we strive to keep content current and accurate, please consult a qualified healthcare professional for personalized medical guidance. Some links on this page are affiliate links — if you purchase through them, we may earn a small commission at no extra cost to you. This helps support our ability to produce quality health content.